Financhill
Back

Karyopharm Therapeutics 10K Form

Buy
69

KPTI
Karyopharm Therapeutics

Last Price:
1.50
Seasonality Move:
-7.77%

7 Day Trial

ALL ACCESS PASS

$ 7

Receive KPTI News And Ratings

See the #1 stock for the next 7 days that we like better than KPTI

KPTI Financial Statistics

Sales & Book Value

Annual Sales: $146.03M
Cash Flow: $-18.59M
Price / Cash Flow: 0
Annual Sales: $-1.19
Price / Book: 0

Profitability

EPS (TTM): -1.25000
Net Income (TTM): $-143.1M
Gross Margin: $141.09M
Return on Equity: 0%
Return on Assets: -47.95%

Karyopharm Therapeutics Earnings Forecast

Key Karyopharm Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 11 years for KPTI is 96.62%.
  • The Selling, General & Administrative Expenses for KPTI have been equal to 90.31% of Gross Profit Margin.
  • The Research & Development expenses have been 95.01% of Revenue.
  • The Interest Expense is -16.65% of Operating Income.
  • The Net Earning history of KPTI is -97.99% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 6 years.

Karyopharm Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: KPTI
CUSIP: 48576U
Website: karyopharm.com

Debt

Debt-to-Equity Ratio: -1.25
Current Ratio: 3.37
Quick Ratio: 3.14

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

KPTI Technical Analysis vs Fundamental Analysis

Buy
69
Karyopharm Therapeutics (KPTI) is a Buy

Is Karyopharm Therapeutics a Buy or a Sell?